p53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 983-988

  Uramoto, Hidetaka ^a   Sugio, Kenji ^a   Oyama, Tsunehiro ^a   Hanagiri, Takeshi ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Immunohistochemical analysis; Non small cell lung cancer; p53; p53r2

Indexed keywords

PARATHION; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; COHORT STUDIES; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES;

EID: 33645827807     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 48: 6-29, 1998.
2. Osada H and Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21: 7421-7434, 2002.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
5. Jordan A and Reichard P: Ribonucleotide reductases. Annu Rev Biochem 67: 71-98, 1998.
6. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49, 2000.
7. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y and Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276: 40647-40651, 2001.
8. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y and Arakawa H: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61: 8256-8262, 2001.
9. Lozano G and Elledge SJ: p53 sends nucleotides to repair DNA. Nature 404: 24-25, 2000.
10. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
11. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y and Yasumoto K: Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462-1465, 1999.
12. Dobashi K, Sugio K, Osaki, T, Oka T and Yasumoto K: Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 114: 339-346, 1997.
13. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, Sugio K, Yasumoto K and Sugimachi K: p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 6: 9-13, 1995.
14. Weinert T: DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 94: 555-558, 1998.
15. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
16. Ford JM and Hanawalt PC: Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc Natl Acad Sci USA 92: 8876-8880, 1995.
17. Ford JM and Hanawalt PC: Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 272: 28073-28080, 1997.
18. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y and Arakawa H: Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34: 440-445, 2003.
19. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K and Kohno K: p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-31702, 2002.
20. Uramoto H, Izumi H, Nagatani G, Ohmori H, Nagasue N, Ise T, Yoshida T, Yasumoto K and Kohno K: Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 371: 301-310, 2003.
21. Nakano K, Balint E, Ashcroft M and Vousden KH: A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19: 4283-4289, 2000.
22. Yanamoto S, Kawasaki G, Yoshitomi I and Mizuno A: Expression of p53R2, new p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett 190: 233-243, 2003.
23. Byun DS, Chae KS, Ryu BK, Lee MG and Chi SG: Expression and mutation analyses of p53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer 98: 718-723, 2002.
24. Inoue M, Osaki T, Noguchi M, Hirohashi S, Yasumoto K and Kasai H: Lung cancer patients have increased 8-hydroxy-deoxyguanosine levels in peripheral lung tissue DNA. Jpn J Cancer Res 89: 691-695, 1998.
25. Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6: 4055-4063, 2000.
26. Ghosh S, Ahmed K, Hopkinson DN and Vaughan R: Pulmonary adenocarcinoma is associated with poor long-term survival after surgical resection. Cancer 101: 2058-2066, 2004.
27. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
28. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K and Kuwano M: Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7: 3151-3155, 2001.
29. Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M, Sugio K and Yasumoto K: Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non small-cell lung cancer. J Clin Oncol 20: 2930-2936, 2002.
30. Gu C, Oyama T, Osaki T, Kohno K and Yasumoto K: Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res 21: 2357-2362, 2001.
31. Yasumoto K, Osaki T, Watanabe Y, Kato H and Yoshimura T: Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected non-small cell lung cancer: a multicenter prospective study. Ann Thorac Surg 76: 194-201, 2003.
32. Osaki T, Mitsudomi T, Oyama T, Nakanishi R and Yasumoto K: Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108: 157-162, 1995.
33. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, Yasumoto K, Sugimachi K and Gazdar AF: Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 2: 1185-1189, 1996.
34. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K and Sasazuki T: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903-2906, 1992.
35. Sugio K, Inoue T, Inoue K, Yaita H, Inuzuka S, Ishida T and Sugimachi K: Different site mutation of the K-ras gene in a patient with metachronous double lung cancers. Anticancer Res 13: 2469-2471, 1993
36. Yanamoto S, Iwamoto T, Kawasaki G, Yoshitomi I, Baba N and Mizuno A: Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223: 67-76, 2005.
37. Ye Z and Parry JM: The discovery and confirmation of single nucleotide polymorphisms in the human p53R2 gene by EST database analysis. Mutagenesis 17: 361-364, 2002.
38. Smeds J, Kumar R and Hemminki K: Polymorphic insertion of additional repeat within an area of direct 8 bp tandem repeats in the 5′-untranslated region of the p53R2 gene and cancer risk. Mutagenesis 16: 547-550, 2001.
39. Hayashi H, Furihata M, Kuwahara M, Kagawa S, Shuin T and Ohtsuki Y: Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract. Pathobiology 71: 103-106, 2004.